Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Transporter-Mediated Disposition, Clinical Pharmacokinetics and Cholestatic Potential of Glyburide and Its Primary Active Metabolites.

Li R, Bi YA, Vildhede A, Scialis RJ, Mathialagan S, Yang X, Marroquin LD, Lin J, Varma MVS.

Drug Metab Dispos. 2017 Jul;45(7):737-747. doi: 10.1124/dmd.116.074815. Epub 2017 Apr 24.

PMID:
28438781
2.

Assessment of Bile Salt Export Pump (BSEP) Inhibition in Membrane Vesicles Using Radioactive and LC/MS-Based Detection Methods.

Marroquin LD, Bonin PD, Keefer J, Schroeter T.

Curr Protoc Toxicol. 2017 Feb 1;71:14.14.1-14.14.20. doi: 10.1002/cptx.15.

PMID:
28146280
3.

Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis.

Lapham K, Novak J, Marroquin LD, Swiss R, Qin S, Strock CJ, Scialis R, Aleo MD, Schroeter T, Eng H, Rodrigues AD, Kalgutkar AS.

Chem Res Toxicol. 2016 Oct 17;29(10):1778-1788. doi: 10.1021/acs.chemrestox.6b00262. Epub 2016 Oct 4.

PMID:
27676153
4.

Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.

Torti VR, Wojciechowicz D, Hu W, John-Baptiste A, Evering W, Troche G, Marroquin LD, Smeal T, Yamazaki S, Palmer CL, Burns-Naas LA, Bagrodia S.

Mol Cancer Ther. 2012 Oct;11(10):2274-83. doi: 10.1158/1535-7163.MCT-11-0984. Epub 2012 Jul 2.

5.

Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase.

Hu W, Lu S, McAlpine I, Jamieson JD, Lee DU, Marroquin LD, Heyen JR, Jessen BA.

Toxicol Sci. 2012 Sep;129(1):188-99. doi: 10.1093/toxsci/kfs192. Epub 2012 May 28.

PMID:
22641616
6.

Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.

Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, Hynes J, Patyna S, Jessen BA.

Toxicol Sci. 2008 Nov;106(1):153-61. doi: 10.1093/toxsci/kfn157. Epub 2008 Jul 29.

PMID:
18664550
7.

In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone.

Dykens JA, Jamieson JD, Marroquin LD, Nadanaciva S, Xu JJ, Dunn MC, Smith AR, Will Y.

Toxicol Sci. 2008 Jun;103(2):335-45. doi: 10.1093/toxsci/kfn056. Epub 2008 Mar 15.

PMID:
18344530
8.

Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants.

Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y.

Toxicol Sci. 2007 Jun;97(2):539-47. Epub 2007 Mar 14.

PMID:
17361016
9.

Strategies to reduce late-stage drug attrition due to mitochondrial toxicity.

Dykens JA, Marroquin LD, Will Y.

Expert Rev Mol Diagn. 2007 Mar;7(2):161-75. Review.

PMID:
17331064
10.

Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes.

Hynes J, Marroquin LD, Ogurtsov VI, Christiansen KN, Stevens GJ, Papkovsky DB, Will Y.

Toxicol Sci. 2006 Jul;92(1):186-200. Epub 2006 Apr 25.

PMID:
16638925
11.

Resistance to a bacterial toxin is mediated by removal of a conserved glycosylation pathway required for toxin-host interactions.

Griffitts JS, Huffman DL, Whitacre JL, Barrows BD, Marroquin LD, Müller R, Brown JR, Hennet T, Esko JD, Aroian RV.

J Biol Chem. 2003 Nov 14;278(46):45594-602. Epub 2003 Aug 27.

12.

Bacillus thuringiensis (Bt) toxin susceptibility and isolation of resistance mutants in the nematode Caenorhabditis elegans.

Marroquin LD, Elyassnia D, Griffitts JS, Feitelson JS, Aroian RV.

Genetics. 2000 Aug;155(4):1693-9.

Supplemental Content

Loading ...
Support Center